Director Mats Wahlstrom filed a Form 4 with the SEC on November 16, 2026, disclosing a purchase of 50,000 shares of TriSalus Life Sciences, Inc. common stock on November 12, 2026.
Key Highlights
- Transaction: Mats Wahlstrom acquired 50,000 shares of common stock on November 12, 2026, with transaction code P (purchase).
- Price paid: $2.24 per share, according to the filing.
- Direct holdings after transaction: 197,555 shares held directly by the reporting person.
- Indirect holdings via Leonard Capital LLC: 1,444,447 shares, held indirectly; Wahlstrom shares voting and investment discretion with his spouse.
- Indirect holdings via HW Investment Partners, LLC: 1,370,028 shares, held indirectly; Wahlstrom is a managing member and disclaims beneficial ownership except to the extent of his pecuniary interest.
- Role: Wahlstrom is identified as a Director of TriSalus Life Sciences, Inc. (NASDAQ:TLSI).
Wahlstrom's November 2026 Open-Market Purchase of TriSalus Common Stock
According to the Form 4 filed on November 16, 2026, Mats Wahlstrom, a director of TriSalus Life Sciences, Inc. (NASDAQ:TLSI), purchased 50,000 shares of the company's common stock on November 12, 2026, at a price of $2.24 per share. The transaction is coded "P," indicating an open-market purchase. Following this acquisition, the filing reports that Wahlstrom directly holds 197,555 shares.
The filing also discloses two categories of indirect beneficial ownership. First, 1,444,447 shares are held by Leonard Capital LLC, with respect to which Wahlstrom shares voting and investment discretion with his spouse. Second, 1,370,028 shares are held by HW Investment Partners, LLC, of which Wahlstrom is a managing member sharing voting and investment discretion. The filing states that Wahlstrom "disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein" with respect to the HW Investment Partners, LLC holdings.
The form was signed by Mary Szela as Attorney-in-Fact on November 16, 2026. No derivative securities transactions were reported. The filing indicates this was submitted by one reporting person and is not an amendment to a prior filing.
What Was Disclosed
Director Mats Wahlstrom reported a purchase of 50,000 shares of TriSalus Life Sciences common stock at $2.24 per share on November 12, 2026, bringing his direct holdings to 197,555 shares, with additional indirect holdings through two entities.




Please wait processing your request...